 |
 |
Parkinson's Disease Clinical Trials will Include Co-Enzyme Q10 (CoQ10) Creatine Minocycline and GPI-1485 Treatment Options February 26th 2006 Parkinson's Disease Clinical Trials will Include Co-Enzyme Q10 (CoQ10) Creatine Minocycline and GPI-1485 Treatment Options Coenzyme Q-10 The Government is looking at substances that may offer hope in slowing the progression of Parkinson’s disease, as opposed to just treating the symptoms. Various compounds will be tested including Co-Enzyme Q-10 (CoQ10), creatine, minocycline and GPI-1485. The National Institutes of Health (NIH) is finalizing plans to enroll hundreds of early-stage Parkinson’s patients in this study. An earlier study funded by the NIH found that creatine and minocycline may warrant further consideration. Dr. Karl Kieburtz of the University of Rochester told the World Parkinson Congress last week that while the news is encouraging, the results do not demonstrate that these agents are effective in Parkinson’s disease. His results will be published the March 14 issue of Neurology. The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) have organized a nationwide multi-center effort called NET-PD (Neuroprotection Exploratory Trials in Parkinson's Disease). ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn